- Market Size Overview
- Market Dynamics
- Segmentation Insights
- Regional Insights
- Competitive Overview
- Recent Developments
- Scope of the Report
- List of Segments Covered
- FAQs

Global Cell And Gene Therapy CDMO Market Size, Share, Trends & Growth Analysis Report Segmented By Phase (Pre-clinical, Clinical), Product Type, Indication, And Regions (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), 2026-2034
Cell and Gene Therapy CDMO Market Size and Share
The global cell and gene therapy CDMO market size was valued at USD 7.47 Billion in 2025 and is projected to grow from USD 8.84 Billion in 2026 to USD 34.04 Billion by 2034, at a CAGR of 18.36% during the forecast period. North America dominated the cell and gene therapy CDMO market with a market share of 44.97% in 2025.
The cell and gene therapy CDMO market is evolving as pharmaceutical innovators increasingly rely on specialized manufacturing partners to accelerate clinical development and commercialization. Growing demand for personalized therapies, combined with expanding regulatory support for advanced medicinal products, continues to reshape industry priorities. Global financing for the cell and gene therapy sector reached billions of dollars in recent years, reflecting sustained investor confidence despite broader biotechnology market fluctuations. Meanwhile, the U.S. Food and Drug Administration has approved a steadily rising number of cell and gene therapies, reinforcing commercial momentum. Consequently, cell and gene therapy CDMO market demand continues strengthening as developers seek flexible, compliant manufacturing solutions capable of supporting increasingly sophisticated therapeutic pipelines.
Cell and Gene Therapy CDMO Market Key Takeaways
Market Size & Forecast
2025 Market Size: USD 7.47 Billion
2026 Market Size: USD 8.84 Billion
2034 Projected Market Size: USD 34.04 Billion
CAGR (2026-2034): 18.36%
Largest market: North America
Fastest-growing market: Asia Pacific
Market Share Analysis
- North America held the largest market share of 44.97% in 2025.
- Asia Pacific is expected to expand at a CAGR of 14.91% over the assessment timeline.
- Based on phase, pre-clinical held the dominant share of 63.79% in 2025.
- In terms of product type, cell therapy held the dominant share of 71.19% in 2025, while gene therapy is expected to grow at a CAGR of 18.06% over the assessment timeline.
- Across indication, oncology accounted for 48.79% market share in 2025.
Key Country Highlights
- The U.S. market is expected to grow significantly at a CAGR of 29.33% over the forecast period.
- The Japan market is projected to experience substantial growth during the forecast period.
Cell and Gene Therapy CDMO Market Trends & Future Outlook
Growing demand for decentralized manufacturing and flexible production capacity is reshaping the market. Hundreds of therapy candidates remain in clinical development globally, encouraging CDMOs to expand modular facilities, strengthen digital manufacturing capabilities, and support rising cell and gene therapy CDMO market demand.
Automation and advanced analytics are transforming manufacturing workflows by improving consistency and accelerating batch release. According to the U.S. Food and Drug Administration, increasing approvals for advanced therapies encourage investment in standardized processes and quality-by-design practices, reducing production variability while sustaining market demand.
Strategic collaborations between biotechnology innovators and specialized CDMOs are shaping future market expansion. Substantial investment activity continues supporting advanced therapeutics, while partnerships focused on integrated development, supply chain coordination, and global manufacturing networks reinforce cell and gene therapy CDMO market demand.
Impact of AI in the Cell and Gene Therapy CDMO Market
Artificial intelligence is transforming the market by improving manufacturing precision, accelerating process development, and strengthening quality assurance. According to the U.S. Food and Drug Administration, increasing approvals for advanced therapies are driving demand for efficient manufacturing systems. AI-powered predictive analytics identifies process deviations before production failures occur, minimizing costly batch losses. According to the National Institute of Standards and Technology, digital manufacturing enhances process consistency through real-time monitoring and automated quality control. Machine learning also optimizes facility scheduling, raw material utilization, and supply chain planning, helping CDMOs improve efficiency while supporting faster commercialization of advanced therapies.
Cell and Gene Therapy CDMO Market Investment Analysis
Investment activity in the market continues to grow as pharmaceutical companies, institutional investors, and private equity firms expand funding for advanced manufacturing infrastructure. The sector attracts billions of dollars in annual financing, reflecting strong commercialization confidence. Regulatory progress and increasing therapy approvals encourage investment in automation, specialized production facilities, and quality systems. Although high development costs and regulatory complexity remain investment risks, rising outsourcing trends support long-term returns. Consequently, market investment analysis highlights sustained capital inflows driven by innovation, expanding cell and gene therapy CDMO market demand, and strategic manufacturing partnerships.
Emerging Innovations in Cell and Gene Therapy CDMO Market
Continuous manufacturing technologies are improving production flexibility for advanced therapies. According to the U.S. Food and Drug Administration, growing approvals for cell and gene therapies encourage CDMOs to adopt automated, closed-system manufacturing that minimizes contamination risks, improves reproducibility, and accelerates commercial-scale production across increasingly complex therapeutic programs.
Digital twins and AI-driven process simulation are reshaping manufacturing optimization. According to the National Institute of Standards and Technology, advanced digital manufacturing improves process monitoring and operational consistency, enabling CDMOs to predict performance, reduce production variability, and shorten technology transfer timelines while supporting reliable therapeutic manufacturing outcomes.
Advanced cryopreservation and smart cold-chain technologies are enhancing product stability throughout global distribution. Expanding commercialization of advanced therapies increases demand for secure logistics solutions that preserve product integrity, reduce transportation risks, and strengthen worldwide patient access through dependable supply chain performance.
Cell and Gene Therapy CDMO Market Dynamics
Market Drivers
The primary driver for the market is the rapid expansion of advanced therapy pipelines, compelling biotechnology companies to outsource manufacturing to specialized partners with regulatory expertise and scalable infrastructure. Thousands of regenerative medicine programs are progressing globally, creating sustained production requirements. The U.S. Food and Drug Administration continues approving innovative cell and gene therapies, increasing commercial manufacturing demand. Rising investment in automated production, closed-system processing, and quality-by-design frameworks further enhances manufacturing efficiency, enabling CDMOs to shorten development timelines while improving compliance. These developments continue strengthening the cell and gene therapy CDMO market share across established and emerging manufacturing hubs.
Market Restraints
Despite promising growth prospects, the market faces constraints related to high manufacturing costs, complex production workflows, and stringent regulatory expectations. According to the U.S. Food and Drug Administration, advanced therapies require extensive quality validation before commercialization, increasing operational expenses and extending production timelines. Manufacturing living cells and viral vectors also demands specialized facilities, skilled personnel, and highly controlled environments that limit rapid capacity expansion. Funding volatility within the biotechnology sector can delay outsourcing decisions and facility investments. These operational challenges continue influencing the competitive cell and gene therapy CDMO market share across global service providers.
Market Opportunities
Growing commercialization of personalized medicines presents substantial opportunities for the market as developers increasingly seek integrated manufacturing partners capable of supporting clinical and commercial production. Investment activity continues supporting innovation despite periodic financing fluctuations. Expanding regulatory pathways for advanced therapies encourage CDMOs to invest in digital manufacturing, automation, and end-to-end development services. Emerging healthcare markets are also increasing biotechnology investments to strengthen domestic manufacturing capabilities. These trends enable service providers to diversify operations, expand international partnerships, and reinforce their competitive market share through specialized manufacturing expertise and scalable infrastructure.
Market Challenges
Scaling advanced therapy manufacturing while maintaining consistent product quality remains one of the most significant challenges facing the cell and gene therapy CDMO market. According to the National Institute of Standards and Technology, advanced manufacturing processes require rigorous monitoring to ensure reproducibility across production batches. The U.S. Food and Drug Administration also maintains strict compliance expectations for process validation, documentation, and product traceability, increasing operational complexity. Supply chain disruptions affecting specialized raw materials and viral vector components further challenge production schedules. Successfully overcoming these barriers will determine long-term competitiveness and strengthen cell and gene therapy CDMO market share among leading global manufacturing organizations.
Cell and Gene Therapy CDMO Market Segmentation Insights
Cell and Gene Therapy CDMO Market Analysis, By Phase
By phase, the market is categorized into pre-clinical and clinical.
Pre-clinical held the largest 63.79% market share in 2025, driven by increasing outsourcing of process development, analytical testing, and manufacturing optimization before clinical trials. Growing emphasis on regulatory readiness and scalable production capabilities continues strengthening the cell and gene therapy CDMO market size through sustained demand for specialized early-stage manufacturing services. Clinical is expected to witness the fastest growth during the forecast period as expanding advanced therapy pipelines increase demand for commercial-scale manufacturing and regulatory expertise. Growing clinical activity supports greater outsourcing, reinforcing cell and gene therapy CDMO market growth through integrated development and production capabilities.
Cell and Gene Therapy CDMO Market Analysis, By Product Type
By product type, the market is categorized into gene therapy (ex-vivo, in-vivo), gene-modified cell therapy (CAR T-cell therapies, CAR-NK cell therapy, TCR-T cell therapy, other), and cell therapy.
Cell therapy dominated with a 71.19% market share in 2025, supported by increasing commercialization of autologous and allogeneic therapies. Rising approvals and outsourcing requirements continue expanding the cell and gene therapy CDMO market size, encouraging manufacturers to strengthen specialized production capacity and quality management capabilities. Gene therapy is projected to grow at a CAGR of 18.06% during the assessment period, driven by expanding genetic medicine pipelines and viral vector innovation. Increasing regulatory support and investment in advanced manufacturing continue accelerating cell and gene therapy CDMO market growth, strengthening demand for specialized CDMO expertise.
Cell and Gene Therapy CDMO Market Analysis, By Indication
By indication, the market is categorized into oncology, infectious diseases, neurological disorders, rare diseases, and others.
Oncology accounted for the largest 48.79% market share in 2025, driven by expanding immunotherapy research and commercialization of personalized cancer treatments. Rising oncology clinical programs continue increasing the cell and gene therapy CDMO market size, supporting demand for specialized manufacturing, process development, and regulatory services. Rare diseases are expected to experience the fastest growth during the forecast period as orphan drug incentives and advances in genetic medicine accelerate therapy development. Increasing investment in precision medicine continues supporting cell and gene therapy CDMO market growth, encouraging greater outsourcing of specialized manufacturing and commercialization services.
Cell and Gene Therapy CDMO Market Regional Insights
North America Cell and Gene Therapy CDMO Market
North America held the largest 44.97% market share in 2025, supported by a mature biotechnology ecosystem, advanced manufacturing infrastructure, and favorable regulatory pathways. According to the U.S. Food and Drug Administration, increasing approvals of advanced therapies continue driving outsourcing demand for specialized manufacturing services. Strong investment in automation, viral vector production, and commercial-scale facilities further strengthens regional competitiveness. Strategic collaborations between biotechnology innovators and CDMOs, combined with experienced regulatory expertise and robust research capabilities, continue positioning North America as the leading hub for advanced cell and gene therapy manufacturing.
U.S. Cell and Gene Therapy CDMO Market
The U.S. cell and gene therapy CDMO market is projected to grow at a CAGR of 29.33% during the forecast period. Strong biotechnology innovation, expanding clinical pipelines, and increasing regulatory support continue driving manufacturing investments. According to the U.S. Food and Drug Administration, accelerated pathways for advanced therapies encourage commercialization and outsourcing. Leading CDMOs continue expanding manufacturing capacity, adopting digital technologies, and strengthening quality systems. Close collaboration among biotechnology companies, research institutions, and contract manufacturers further supports process innovation and reinforces the country's leadership in advanced therapeutic manufacturing.
Europe Cell and Gene Therapy CDMO Market
Europe remains a significant market supported by established pharmaceutical manufacturing capabilities, collaborative research networks, and strong regulatory oversight. According to the European Medicines Agency, specialized regulatory pathways continue encouraging innovation in advanced therapy medicinal products. Regional CDMOs are expanding manufacturing capacity while investing in automation and process optimization. Collaboration between biotechnology companies, academic institutions, and contract manufacturers accelerates commercialization of innovative therapies. Strong emphasis on quality standards, sustainability, and advanced manufacturing technologies continues strengthening Europe's competitive position within the global market.
U.K. Cell and Gene Therapy CDMO Market
The U.K. continues expanding its role through world-class research institutions, supportive innovation policies, and advanced manufacturing capabilities. According to the Medicines and Healthcare products Regulatory Agency, regulatory initiatives continue encouraging advanced therapy development while maintaining rigorous quality standards. Strong collaboration between academia, biotechnology companies, and CDMOs supports technology commercialization and manufacturing efficiency. Ongoing investment in digital manufacturing, workforce development, and modern production infrastructure continues strengthening the country's position as a preferred destination for advanced therapy manufacturing and development.
Germany Cell and Gene Therapy CDMO Market
Germany plays an important role through advanced pharmaceutical manufacturing infrastructure, engineering expertise, and strong biotechnology research capabilities. According to Germany's Federal Ministry of Education and Research, continued investment in life sciences supports innovation across regenerative medicine. German CDMOs prioritize automation, process optimization, and strict regulatory compliance to deliver reliable manufacturing services. Collaboration between research organizations, healthcare institutions, and biotechnology companies accelerates technological advancement. These strengths continue reinforcing Germany's leadership in advanced therapy manufacturing across the European region.
Asia Pacific Cell and Gene Therapy CDMO Market
The Asia Pacific cell and gene therapy CDMO market is expected to expand at a CAGR of 14.91% over the assessment timeline. Growing biotechnology investment, improving regulatory frameworks, and expanding manufacturing infrastructure continue supporting regional growth. According to the World Health Organization, healthcare investment across Asia continues improving access to advanced medical technologies. Countries throughout the region are strengthening research capabilities while attracting global outsourcing through competitive manufacturing costs and skilled scientific talent. These factors continue enhancing Asia Pacific's position as a strategic manufacturing destination.
China Cell and Gene Therapy CDMO Market
China continues strengthening its position through expanding biotechnology investments, favorable government policies, and increasing manufacturing capacity. According to the National Medical Products Administration, regulatory reforms continue supporting faster evaluation of innovative therapies. Domestic CDMOs are investing in advanced production technologies, viral vector manufacturing, and integrated development services to meet growing demand. Collaboration with international biotechnology companies continues improving manufacturing capabilities and technology transfer. Strong government support, expanding research activity, and commercial production capacity position China as an increasingly important global manufacturing hub.
Japan Cell and Gene Therapy CDMO Market
The Japan cell and gene therapy CDMO market is projected to experience substantial growth during the forecast period. Progressive regenerative medicine regulations and continuous biotechnology investments are supporting commercial expansion. According to Japan's Ministry of Health, Labour and Welfare, regulatory pathways continue encouraging innovation in advanced therapies. Collaboration between research institutes, biotechnology companies, and specialized CDMOs strengthens technology development and manufacturing efficiency. High-quality production standards, scientific expertise, and increasing adoption of personalized medicine continue supporting long-term market development.
India Cell and Gene Therapy CDMO Market
India is steadily strengthening its presence through expanding biotechnology investment, competitive manufacturing capabilities, and an experienced scientific workforce. According to the Department of Biotechnology, government initiatives continue supporting advanced biological research and innovation. Domestic CDMOs are investing in modern manufacturing facilities and international quality standards to serve global pharmaceutical clients. Cost-effective operations, increasing research collaborations, and growing outsourcing demand continue improving India's competitiveness. These developments position the country as an attractive destination for advanced therapy manufacturing and contract development services.
Middle East & Africa Cell and Gene Therapy CDMO Market
The Middle East and Africa cell and gene therapy CDMO market is gradually expanding as governments increase healthcare investment and biotechnology research initiatives. According to the World Health Organization, regional healthcare expenditure continues supporting infrastructure development and specialized medical services. International collaborations are strengthening technology transfer, workforce development, and manufacturing expertise. Although commercial manufacturing capacity remains limited compared with developed regions, increasing investment, regulatory modernization, and growing interest in advanced therapeutics continue creating long-term opportunities for market expansion.
GCC Cell and Gene Therapy CDMO Market
The GCC is emerging as a promising market due to increasing healthcare modernization, biotechnology investment, and pharmaceutical manufacturing initiatives. Governments continue supporting economic diversification through life science development and biomedical research programs. Strategic partnerships with international biotechnology companies facilitate technology transfer and strengthen manufacturing capabilities. Investments in advanced healthcare infrastructure and precision medicine continue expanding opportunities for specialized contract manufacturing. These initiatives are expected to enhance regional competitiveness while supporting long-term development of advanced therapy manufacturing services.
Latin America Cell and Gene Therapy CDMO Market
Latin America is experiencing steady growth as biotechnology research, healthcare investment, and pharmaceutical manufacturing capabilities continue advancing. According to the Pan American Health Organization, regional healthcare modernization is improving access to innovative medical technologies and research infrastructure. Local manufacturers are strengthening partnerships with global biotechnology companies to enhance production capabilities and technology transfer. Continued investment in scientific research, regulatory improvements, and workforce development is expected to support long-term expansion of advanced therapy contract development and manufacturing services.
Cell and Gene Therapy CDMO Market Competitive Overview
The cell and gene therapy CDMO market is characterized by intense competition centered on manufacturing expertise, regulatory compliance, capacity expansion, and end-to-end service integration. Leading companies including Lonza Group AG, Thermo Fisher Scientific Inc. (Patheon), Samsung Biologics, FUJIFILM Diosynth Biotechnologies, and AGC Biologics continue investing in advanced manufacturing technologies, automation, and global facility expansion to strengthen competitive positioning. According to the U.S. Food and Drug Administration, increasing approvals of advanced therapies are driving demand for commercial-scale manufacturing with consistent quality standards. Companies offering integrated development, analytical testing, process optimization, and commercial manufacturing services gain stronger customer retention. Sustainable competitive advantage increasingly depends on technological innovation, regulatory expertise, manufacturing scalability, and the ability to deliver reliable global supply solutions.
Leading Market Players in the Cell and Gene Therapy CDMO Market
- Lonza Group AG: Lonza Group AG is one of the leading participants in the cell and gene therapy CDMO market, recognized for its comprehensive contract development and manufacturing capabilities spanning early research through commercial production. The company emphasizes integrated manufacturing platforms, advanced process development, and regulatory compliance to support developers of complex cell and gene therapies. Its extensive global manufacturing network enables efficient technology transfer while maintaining consistent quality standards. Lonza continuously strengthens its portfolio through innovation, strategic collaborations, and investments in advanced production technologies, positioning itself as a trusted long-term manufacturing partner for biotechnology and pharmaceutical companies worldwide.
- Thermo Fisher Scientific Inc. (Patheon): Thermo Fisher Scientific Inc., through its Patheon business, provides comprehensive development and manufacturing services across the advanced therapeutics value chain. The company focuses on scalable manufacturing solutions, analytical testing, process optimization, and commercial production tailored to evolving customer requirements. Its strong scientific expertise and integrated service model help accelerate clinical development while supporting regulatory compliance throughout product lifecycles. By expanding manufacturing infrastructure, strengthening digital capabilities, and fostering strategic partnerships with biotechnology innovators, Thermo Fisher Scientific continues reinforcing its leadership position within the highly specialized cell and gene therapy CDMO market.
- Samsung Biologics: Samsung Biologics has established itself as a prominent contract development and manufacturing organization by combining advanced manufacturing technologies with large-scale production expertise. The company continues expanding its capabilities in biologics and advanced therapies through investments in modern facilities, digital manufacturing systems, and operational excellence initiatives. Its customer-focused approach emphasizes flexibility, quality assurance, and efficient project execution from development through commercialization. Strategic collaborations with global biotechnology and pharmaceutical companies further strengthen Samsung Biologics' competitive position while enabling the delivery of reliable manufacturing solutions that support the growing demand for advanced therapeutic products.
List of Companies Profiled in the Report are:
By Phase By Product Type By Indication
Global Cell And Gene Therapy CDMO Market Report Scope and Key Segmentation
Attributes
Report Details
2025 Market Size USD 7.47 Billion 2026 Market Size USD 8.84 Billion 2034 Revenue Forecast USD 34.04 Billion Growth Rate 18.36% from 2026-2034 Study Period 2026-2034 Units Used USD Billion Key Segments Geographical Coverage Companies Profiled
*List of companies to be profiled in the report can be customized.
Analyst’s View on the Cell and Gene Therapy CDMO Market
- Increasing regulatory approvals for advanced therapies are accelerating outsourcing trends, encouraging CDMOs to expand specialized manufacturing infrastructure. Companies capable of integrating automation, quality systems, and flexible production platforms are expected to strengthen long-term competitive positioning while improving overall market share.
- Strategic partnerships between biotechnology innovators and specialized manufacturing organizations will increasingly determine commercial success. Organizations offering integrated development, analytical testing, regulatory support, and commercial manufacturing services are likely to secure stronger customer relationships and higher-value outsourcing contracts.
- Continued investment in digital manufacturing, artificial intelligence, and automated production technologies is expected to improve manufacturing consistency, reduce operational risks, and accelerate technology transfer, allowing CDMOs to respond efficiently to growing demand for personalized and complex therapeutic products.
- Expanding manufacturing capacity across North America and Asia Pacific is expected to improve global supply resilience while enabling companies to support larger commercial production volumes. Geographic diversification will remain an important competitive strategy as advanced therapy pipelines continue expanding worldwide.
- Although manufacturing complexity, regulatory compliance, and specialized workforce requirements remain significant operational challenges, companies investing consistently in innovation, process optimization, and scalable infrastructure are expected to achieve stronger long-term growth and sustain leadership within the evolving competitive landscape.
List of Segments Covered
This section of the market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Phase By Product Type By Indication
Frequently Asked Questions (FAQs) about this Report
How big is the Global Cell And Gene Therapy CDMO market?
What is the Global Cell And Gene Therapy CDMO market growth?
Which region holds the highest share in the Global Cell And Gene Therapy CDMO market?
How is the Global Cell And Gene Therapy CDMO market segmented in the report?
Which segment accounted for the largest cell and gene therapy CDMO market share?
What are the factors driving the cell and gene therapy CDMO market?
Who are the key players in the Global Cell And Gene Therapy CDMO market?
Author

Chitra Patil
Senior Market Research Analyst – Healthcare & Life Sciences
Chitra Patil is a market research professional with over 7+ years of experience in the Healthcare & Life Sciences industry. She specializes in delivering comprehensive market intelligence across diverse healthcare segments, including Healthcare Services, Healthcare IT, Medical Devices, Pharmaceuticals, Biotechnology, and Animal Nutrition and Wellness. Her work focuses on identifying emerging trends, evaluating market dynamics, and providing actionable insights that support strategic business decisions in regulated healthcare environments. Her professional responsibilities include market sizing, growth forecasting, demand analysis, competitive intelligence, and evaluation of technological innovations in healthcare delivery systems and life sciences products. She has successfully contributed to the development of multiple healthcare-focused research studies that support manufacturers, healthcare providers, technology firms, and pharmaceutical stakeholders.
Read more about Chitra PatilCOMPANY
CONTACT
UG-203, Gera Imperium Rise, Wipro Circle Metro Station, Hinjawadi, Pune - 411057
- sales@valuemarketresearch.com
- +1-888-294-1147
BUSINESS HOURS
Monday to Friday : 9 A.M IST to 6 P.M IST
Saturday-Sunday : Closed
Email Support : 24 x 7
© , All Rights Reserved, Value Market Research